. Author manuscript; available in PMC: 2024 Feb 13.

Published in final edited form as: Int J Radiat Oncol Biol Phys. 2015 Dec 14;95(1):488–497. doi: 10.1016/j.ijrobp.2015.11.043

Table 1.

Motion robust IMPT achieves improved heart, lung, and liver sparing compared with PSPT and VMAT for esophageal cancer

Parameter	Motion robust IMPT	PSPT	VMAT	P

Heart mean [Gy(RBE)]	9.9 ± 3.1	12.3 ± 3.2		.001
			17.1 ± 4.2	.001
Heart V40 (%)	9.2 ± 4.4	13.9 ± 4.8		.001
			8.5 ± 5.0	.3
Lung mean [Gy(RBE)]	3.0 ± 0.9	4.4 ± 1.3		.001
			6.3 ± 1.3	.001
Lung V5 (%)	11.4 ± 3.4	18.7 ± 5.6		.001
			36.0 ± 8.8	.001
Lung V20 (%)	5.7 ± 1.7	7.9 ± 2.3		.002
			8.1 ± 1.9	.001
Liver mean [Gy(RBE)]	4.0 ± 2.5	3.5 ± 1.6		.13
			9.8 ± 3.1	.002
Liver V30 (%)	5.4 ± 3.0	6.0 ± 2.8		.04
			7.0 ± 2.6	.01

Abbreviations: IMPT = intensity modulated proton therapy; PSPT = passive scattering proton therapy; RBE = relative biological effectiveness; VMAT = volumetric modulated arc therapy.

Values are mean ± standard deviation.